AFP and hepatocellular carcinoma: AASLD guidelines for managing CHB recommend screening of persons at high risk for HCC by ultrasound (US) every 6–12 months, but list serum alpha-fetoprotein (AFP) as an acceptable alternative in areas of the United States where US is not readily available (5).